Known targets — ChEMBL curated mechanism
KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2
The experimentally established mechanism targets of Guanidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | TTR | P02766 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.47 |
| ▸ | PTGES | O14684 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL527543 | 0.94 | MAPT (0.71) | MAPTCYP1A2CYP2C9KMT2AALDH1A1 | |
| SCHEMBL30727558 | 0.94 | MAPT (0.71) | MAPTCYP1A2CYP2C9KMT2AALDH1A1 | |
| SCHEMBL7330416 | 0.86 | PRSS1 (0.61) | MAPTCYP1A2CYP2C9KMT2AALDH1A1 | |
| SCHEMBL16335592 | 0.85 | MAPT (0.60) | MAPTCYP1A2CYP2C9KMT2AALDH1A1 | |
| SCHEMBL3150116 | 0.84 | MAPT (0.63) | MAPTCYP1A2CYP2C9KMT2AALDH1A1 | |
| SCHEMBL17165000 | 0.84 | MAPT (0.68) | MAPTCYP1A2CYP2C9KMT2AALDH1A1 | |
| SCHEMBL4005710 | 0.84 | MAPT (0.53) | MAPTCYP1A2CYP2C9KMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL7865524 | 0.83 | MAPT (0.52) | MAPTCYP1A2CYP2C9KMT2AALDH1A1 | |
| SCHEMBL3102944 | 0.82 | MAPT (0.57) | MAPTCYP1A2CYP2C9KMT2AALDH1A1 | |
| SCHEMBL4071946 | 0.82 | MAPT (0.60) | MAPTCYP1A2CYP2C9KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140234362-A1 | DEFENSIN-ANTIGEN FUSION PROTEINS | The U.S.A, as represented by the Secretary , Department of Health and Human Services (US) | 2014-08-21 | — | — | US | disclosed |
| US-8754030-B2 | Defensin-antigen fusion proteins | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-06-17 | — | — | US | disclosed |
| US-20140004113-A1 | DEFENSIN-ANTIGEN FUSION PROTEINS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN (US) | 2014-01-02 | — | — | US | disclosed |
| US-8551936-B2 | Defensin-antigen fusion proteins | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2013-10-08 | — | — | US | disclosed |
| US-20130224199-A1 | VIRAL CHEMOKINE-ANTIGEN FUSION PROTEINS | SERVICES (US) | 2013-08-29 | — | — | US | disclosed |
| US-8460675-B2 | Viral chemokine-antigen fusion proteins | The United States of America, as represented by the Secretary, Department of the Health and Human Services (US) | 2013-06-11 | — | — | US | disclosed |
| US-8318177-B2 | Viral chemokine-antigen fusion proteins | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-11-27 | — | — | US | disclosed |
| US-20120276101-A1 | VIRAL CHEMOKINE-ANTIGEN FUSION PROTEINS | The U.S.of America as represented by the Secretary, Department of Health and Human Services | 2012-11-01 | — | — | US | disclosed |
| US-20120134954-A1 | DEFENSIN-ANTIGEN FUSION PROTEINS | THE GOV. OF THE U.S.A. AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH & HUMAN SERVICES | 2012-05-31 | — | — | US | disclosed |
| US-8084250-B2 | Defensin-antigen fusion proteins | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-12-27 | — | — | US | disclosed |
| US-20100260793-A1 | DEFENSIN-ANTIGEN FUSION PROTEINS | The Govt. of USA. as represented by the Secretary of the Dept. of Health and Human Services | 2010-10-14 | — | — | US | disclosed |
| US-7754676-B2 | Cancer and viral infections vaccines; increased immunogenicity | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-07-13 | — | — | US | disclosed |
| US-20050095257-A1 | Cancer and viral infections vaccines; increased immunogenicity | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, C/O NATIONAL INSTITUTES OF HEALTH, OFFICE OF TECHNOLOGY TRANSFER | 2005-05-05 | — | — | US | disclosed |
| US-20040110165-A1 | Viral chemokine-antigen fusion proteins | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2004-06-10 | — | — | US | disclosed |
| US-20030138452-A1 | Chemokine-tumor antigen fusion proteins as cancer vaccines | KWAK LARRY W (US) | 2003-07-24 | — | — | US | disclosed |
| US-6562347-B1 | Eliciting immune response for cancer treatment or human immunodeficiency virus infection prevention or treatment | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2003-05-13 | — | — | US | disclosed |
| WO-2003025002-A2 | METHOD AND COMPOSITIONS OF DEFENSIN-ANTIGEN FUSION PROTEINS AND CHEMOKINE-ANTIGEN FUSION PROTEINS AS VACCINES FOR TUMORS AND VIRAL INFECTION | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2003-03-27 | — | — | WO | disclosed |
| WO-2002022686-A2 | DEFENSIN-ANTIGEN FUSION PROTEINS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH, OFFICE OF TECHNOLOGY TRANSFER (US) | 2002-03-21 | — | — | WO | disclosed |
| WO-2002022687-A2 | VIRAL CHEMOKINE-TUMUR ANTIGEN FUSION PROTEINS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2002-03-21 | — | — | WO | disclosed |
| WO-1999046392-A1 | METHODS AND COMPOSITIONS OF CHEMOKINE-TUMOR ANTIGEN FUSION PROTEINS AS CANCER VACCINES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-09-16 | — | — | WO | disclosed |